Literature DB >> 23456101

Development of a placebo effect model combined with a dropout model for bipolar disorder.

Wan Sun1, Thomas P Laughren, Hao Zhu, Guenther Hochhaus, Yaning Wang.   

Abstract

The aim of this study was to develop a placebo model for bipolar disorder to help optimize clinical trial designs for studies targeting manic episodes in bipolar disorder. A bipolar disease database was built based on individual longitudinal data collected from over 3,000 patients in 11 clinical trials for 5 approved bipolar drugs. An empirical placebo effect model with an exponential decay process plus a linear progression process was developed to quantify the time course of the Young Mania Rating Scale total score based on only placebo data from the database. In order to describe the dropout pattern during the trials, a parametric survival model was developed and the Weibull distribution was identified to be the best distribution to describe the data. Based on the likelihood ratio test, it was found that patients with higher baseline score, slower disease improvement and more rapid disease progression tended to dropout earlier, and the trial features such as trial starting year and trial site were also significant covariates for dropout. A combination of the placebo effect model and the dropout model was applied to simulate new clinical trials through Monte-Carlo simulation. Both the placebo effect model and dropout model described the observed data reasonably well based on various diagnostic plots. The joint placebo response and dropout models can serve as a tool to simulate the most likely level of placebo response with the expected dropout pattern to help design a new clinical trial.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23456101     DOI: 10.1007/s10928-013-9305-5

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  28 in total

1.  Unbalanced randomization influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials.

Authors:  H C Diener; A J Dowson; M Ferrari; G Nappi; P Tfelt-Hansen
Journal:  Cephalalgia       Date:  1999-10       Impact factor: 6.292

2.  Do many patients with depression suffer from bipolar disorder?

Authors:  Jules Angst
Journal:  Can J Psychiatry       Date:  2006-01       Impact factor: 4.356

Review 3.  Quantitative disease, drug, and trial models.

Authors:  Jogarao V S Gobburu; Lawrence J Lesko
Journal:  Annu Rev Pharmacol Toxicol       Date:  2009       Impact factor: 13.820

4.  Approaches to handling pharmacodynamic baseline responses.

Authors:  Chantaratsamon Dansirikul; Hanna E Silber; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-04-30       Impact factor: 2.745

Review 5.  Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.

Authors:  Mark Sinyor; Anthony J Levitt; Amy H Cheung; Ayal Schaffer; Alex Kiss; Yekta Dowlati; Krista L Lanctôt
Journal:  J Clin Psychiatry       Date:  2010-01-26       Impact factor: 4.384

6.  Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.

Authors:  Ni A Khin; Yeh-Fong Chen; Yang Yang; Peiling Yang; Thomas P Laughren
Journal:  J Clin Psychiatry       Date:  2011-04       Impact factor: 4.384

Review 7.  Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

Authors:  George I Papakostas; Maurizio Fava
Journal:  Eur Neuropsychopharmacol       Date:  2008-09-26       Impact factor: 4.600

Review 8.  Modelling placebo response in depression trials using a longitudinal model with informative dropout.

Authors:  Roberto Gomeni; Agnes Lavergne; Emilio Merlo-Pich
Journal:  Eur J Pharm Sci       Date:  2008-11-08       Impact factor: 4.384

9.  Quantification of disease progression and dropout for Alzheimer's disease.

Authors:  Demiana William-Faltaos; Ying Chen; Yaning Wang; Jogarao Gobburu; Hao Zhu
Journal:  Int J Clin Pharmacol Ther       Date:  2013-02       Impact factor: 1.366

10.  Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.

Authors:  N H Holford; K E Peace
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

View more
  5 in total

Review 1.  Pharmacometrics: The Already-Present Future of Precision Pharmacology.

Authors:  Lorena Cera Bandeira; Leonardo Pinto; Cláudia Martins Carneiro
Journal:  Ther Innov Regul Sci       Date:  2022-08-18       Impact factor: 1.337

2.  Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft mice.

Authors:  Xi-Wei Ji; Shuang-Min Ji; Run-Tao Li; Ke-Hua Wu; Xiao Zhu; Wei Lu; Tian-Yan Zhou
Journal:  Acta Pharmacol Sin       Date:  2016-05-02       Impact factor: 6.150

Review 3.  A review of disease progression models of Parkinson's disease and applications in clinical trials.

Authors:  Charles S Venuto; Nicholas B Potter; E Ray Dorsey; Karl Kieburtz
Journal:  Mov Disord       Date:  2016-05-26       Impact factor: 10.338

Review 4.  Emerging Role of Organ-on-a-Chip Technologies in Quantitative Clinical Pharmacology Evaluation.

Authors:  Nina Isoherranen; Rajanikanth Madabushi; Shiew-Mei Huang
Journal:  Clin Transl Sci       Date:  2019-03       Impact factor: 4.689

5.  An Innovative Disease-Drug-Trial Framework to Guide Binge Eating Disorder Drug Development: A Case Study for Topiramate.

Authors:  Shamir N Kalaria; Susan L McElroy; Jogarao Gobburu; Mathangi Gopalakrishnan
Journal:  Clin Transl Sci       Date:  2019-09-09       Impact factor: 4.689

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.